Literature DB >> 12369891

Assessment of blood-brain barrier penetration: in silico, in vitro and in vivo.

Meihua Rose Feng1.   

Abstract

The amount of drug achieved and maintained in the brain after systemic administration is determined by the agent's permeability at blood-brain barrier (BBB), potential involvement of transport systems, and the distribution, metabolism and elimination properties. Passive diffusion permeability may be predicted by an in silico method based on a molecule's structure property. In vitro cell culture is another useful tool for the assessment of passive permeability and BBB transports (e.g. PGP, MRP). In situ or in vivo techniques like carotid artery single injection or perfusion, brain microdialysis, autoradiography, and others are used at various stages of drug discovery and development to estimate CNS penetration and PK/PD correlation. Each technique has its own application with specific advantages and limitations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12369891     DOI: 10.2174/1389200023337063

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  14 in total

Review 1.  Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery.

Authors:  Mohammad S Alavijeh; Mansoor Chishty; M Zeeshan Qaiser; Alan M Palmer
Journal:  NeuroRx       Date:  2005-10

Review 2.  In vitro blood-brain barrier models: current and perspective technologies.

Authors:  Pooja Naik; Luca Cucullo
Journal:  J Pharm Sci       Date:  2011-12-27       Impact factor: 3.534

3.  The subcellular distribution of small molecules: a meta-analysis.

Authors:  Nan Zheng; Hobart Ng Tsai; Xinyuan Zhang; Kerby Shedden; Gus R Rosania
Journal:  Mol Pharm       Date:  2011-08-17       Impact factor: 4.939

Review 4.  Medicinal chemical properties of successful central nervous system drugs.

Authors:  Hassan Pajouhesh; George R Lenz
Journal:  NeuroRx       Date:  2005-10

5.  Time-dependent changes of oxime K027 concentrations in different parts of rat central nervous system.

Authors:  Jana Zdarova Karasova; Filip Zemek; Kamil Musilek; Kamil Kuca
Journal:  Neurotox Res       Date:  2012-05-15       Impact factor: 3.911

Review 6.  Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats.

Authors:  Joost Westerhout; Bart Ploeger; Jean Smeets; Meindert Danhof; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2012-05-17       Impact factor: 4.009

7.  Investigating Subcellular Compartment Targeting Effect of Porous Coordination Cages for Enhancing Cancer Nanotherapy.

Authors:  Yu Fang; Xizhen Lian; Yanyan Huang; Guo Fu; Zhifeng Xiao; Qi Wang; Beiyan Nan; Jean-Philippe Pellois; Hong-Cai Zhou
Journal:  Small       Date:  2018-09-17       Impact factor: 13.281

Review 8.  On the rate and extent of drug delivery to the brain.

Authors:  Margareta Hammarlund-Udenaes; Markus Fridén; Stina Syvänen; Anubha Gupta
Journal:  Pharm Res       Date:  2007-12-05       Impact factor: 4.200

9.  Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model.

Authors:  Xianhuo Wang; Xingmei Duan; Guangli Yang; Xiaoyan Zhang; Linyu Deng; Hao Zheng; Chongyang Deng; Jiaolin Wen; Ning Wang; Cheng Peng; Xia Zhao; Yuquan Wei; Lijuan Chen
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

10.  Micheliolide derivative DMAMCL inhibits glioma cell growth in vitro and in vivo.

Authors:  Yinghong An; Wanjun Guo; Linna Li; Chengwang Xu; Dexuan Yang; Shanshan Wang; Yaxin Lu; Quan Zhang; Jiadai Zhai; Hongxia Fan; Chuanjiang Qiu; Jie Qi; Yue Chen; Shoujun Yuan
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.